Achieve Life Sciences Announces FDA NDA Acceptance for Cytisinicline in Smoking Cessation

• Achieve Life Sciences announces FDA acceptance of NDA for cytisinicline in smoking cessation. • Cytisinicline is one of nine therapies chosen for FDA's National Priority Voucher. • PDUFA targeted action date is June 20, 2026. • FDA Commissioner's National Priority Voucher aims to address e-cigarette or vaping cessation. • Conference call scheduled for 8:30 AM EST today.